Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab

Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab

Pembrolizumab is a programmed cell death protein 1 (PD-1) monoclonal antibody used in the treatment of metastatic melanomas. Severe ocular complications appear in less than 1% of the patients and require early treatment. We present the case of a patient diagnosed with a BRAF mutated metastatic melan...

Full description

Bibliographic Details
Main Authors: Carmen Navarro-Perea, Javier Garcia-Gonzalez, Eugenio Perez-Blazquez
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Indian Journal of Ophthalmology
Subjects:
ctla-4
melanoma
papillitis
pd-1
pembrolizumab
uveitis
Online Access:http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=12;spage=2075;epage=2077;aulast=Navarro-Perea

Internet

http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=12;spage=2075;epage=2077;aulast=Navarro-Perea

Similar Items